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pothesis generated by observational data that rEPO may 
 improve long-term cognitive outcomes of preterm infants 
suffering from IVH are to be confirmed or refuted by the ran-
domized controlled trial, EpoRepair. 
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 Introduction 
 Despite a perpetual increase in survival rates of very 
preterm infants, the long-term neurodevelopmental 
outcome is still worrying. One of the most consistent 
predictors of neurodevelopmental impairment in pre-
term infants is intraventricular hemorrhage (IVH)  [1–
3] , which is recognized in the first few days of life (DOL) 
by cranial ultrasound, the standard imaging tool for 
the  diagnosis of cerebral lesions in preterm infants 
and graded according to the classification of Papile et al. 
 [4] . 
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 Abstract 
 Background: Preterm infants suffering from intraventricular 
hemorrhage (IVH) are at increased risk for neurodevelop-
mental impairment. Observational data suggest that recom-
binant human erythropoietin (rEPO) improves long-term 
cognitive outcome in infants with IVH. Recent studies re-
vealed a beneficial effect of early high-dose rEPO on white 
matter development in preterm infants determined by mag-
netic resonance imaging (MRI).  Objectives: To summarize 
the current evidence and to delineate the study protocol of 
the EpoRepair trial (Erythropoietin for the Repair of Cerebral 
Injury in Very Preterm Infants).  Methods: The study involves 
a review of the literature and the design of a double-blind, 
placebo-controlled, multicenter trial of repetitive high-dose 
rEPO administration, enrolling 120 very preterm infants with 
moderate-to-severe IVH diagnosed by cranial ultrasound in 
the first days of life, qualitative and quantitative MRI at term-
equivalent age and long-term neurodevelopmental follow-
up until 5 years of age.  Results and Conclusions: The hy-
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 Infants with higher-grade IVH (grade III or IV, the lat-
ter of which is also termed ‘hemorrhagic parenchymal 
 infarction’  [5] ), especially those with posthemorrhagic 
 hydrocephalus, are the most severely affected  [6] . The 
 impact of lower-grade IVH (grade I and II) on the neuro-
development of preterm infants is equivocal. Whereas a 
study from the USA did not find a significant difference 
on neurodevelopmental outcome assessed at 18–22 
months’ corrected age between extremely preterm infants 
with low-grade IVH compared to those without hemor-
rhage  [7] , a study from Australia denoted a negative im-
pact on brain cortical volume, developmental scores and 
neurosensory system at 2–3 years’ corrected age  [8] .
 IVH originates in the germinal matrix, a highly cellular 
and extensively vascularized region, which is the source 
of future neuronal and glial cells of the immature brain 
 [5] . IVH may result in a decline of cerebral growth  [9] , 
direct parenchymal damage and free iron toxicity, con-
tributing further to IVH-mediated brain damage  [10] . 
However, recent findings from brain magnetic resonance 
imaging (MRI) studies led to the assumption that neuro-
developmental disability is primarily associated with im-
paired neural connectivity rather than cell death alone 
 [11] . White matter (WM) abnormalities as defined by 
lower fractional anisotropy in MR diffusion tensor imag-
ing at term-equivalent age (TEA) have been found in pre-
term infants with IVH  [12–14] .
 Whereas the understanding of IVH origin and damage 
has made remarkable progress together with the promis-
ing biomarker tool MRI, there are only few evidence-
based measures to reduce the risk of IVH such as fetal 
lung maturation, late cord clamping  [15, 16] or early pro-
phylactic indomethacin  [17] . Moreover, except for shunt 
insertion to drain cerebrospinal fluid in infants with post-
hemorrhagic hydrocephalus and possibly the removal of 
blood clots in infants with high-grade IVH  [18, 19] , there 
is no treatment for established IVH and no medical ther-
apies exist to ameliorate the neurodevelopmental sequel-
ae of IVH. 
 Potential Benefits and Risks of Erythropoietin in 
Preterm Infants 
 Apart from stimulating the production of red blood 
cells, recombinant human erythropoietin (rEPO) has 
been shown to exert neuroprotective action in a variety of 
animal models with brain damage  [20] . Administration 
of rEPO even several days after the insult can enhance 
neurogenesis and oligodendrogenesis and promotes the 
recovery of neurological function weeks to months after 
the insult  [21] . Of interest, long-term treatment with 
rEPO after an insult in the very immature rat brain in-
duced the recovery of WM microstructures and of con-
nectivity as well as somatosensory cortical function with-
out effects on the total brain volume  [22] . Observational 
data from preterm infants who suffered from IVH and 
who were treated with rEPO to prevent red blood cell 
transfusions showed improved long-term neurodevelop-
mental outcomes when assessed at 3 years of age or more 
 [23] . As they received rEPO within days or weeks after the 
insult, the proposed mode of action of rEPO is thought to 
be the facilitation of repair, the sustainment of neuronal 
growth and differentiation after brain injury, rather than 
protection against damage  [24] . 
 rEPO has proven safe in three decades of randomized 
controlled trials (RCT) evaluating its effect on neonatal 
erythropoiesis  [25] and has gained approval for the use 
in infants by the regulatory authorities of the USA (FDA), 
the European Union (EMA) and Switzerland (Swissmed-
ic). Meta-analyses combining early and late rEPO admin-
istration to prevent anemia of prematurity have raised 
concerns about increased rates of severe retinopathy of 
prematurity associated with the prolonged use of rEPO 
 [26] . Safety issues of high-dose rEPO aimed at crossing 
the blood-brain barrier in preterm infants also remain a 
topic in recent investigations  [27] . The eagerly awaited 
safety data from the first large phase II double-masked 
RCT using high-dose rEPO as a neuroprotective agent 
given shortly after birth (3 × 3,000 U/kg body weight 
(BW) rEPO or NaCl 0.9% within the first 36 h of life) to 
443 very preterm infants describe no relevant differences 
between both groups regarding short-term outcomes, in-
cluding mortality, retinopathy of prematurity and IVH 
incidence (ClinicalTrials.gov identifier: NCT00413946) 
 [28] . A qualitative and quantitative MRI was performed 
in a subset of patients at TEA. The MRI findings show 
that early high-dose rEPO administration resulted in less 
WM and gray matter injury and in improved WM mi-
crostructure  [29, 30] . Neurodevelopmental follow-up of 
the study patients will demonstrate whether these prom-
ising MRI findings will translate into improved long-
term outcomes  [31] . Since the 2-year outcome assess-
ment is limited in predicting later cognitive functions 
and has been considered recently as a proof of safety rath-
er than an efficacy milestone  [32] , we expect that the 
5-year follow-up tests will give answers as to the clinical 
and neuroprotective efficacy of early high-dose rEPO in 
very preterm infants which cannot be provided by the 
2-year examinations. 
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 Open Questions 
 Does rEPO administered to preterm infants with IVH 
improve neurodevelopmental outcome at school age? 
This is being suggested by data from a retrospective anal-
ysis  [23] but the question has not been addressed in an 
RCT. How is the structural brain damage at TEA in pre-
term infants with IVH, as assessed by MRI, influenced by 
early rEPO administration and how are these changes re-
lated to neurodevelopmental outcome at school age?
 Study Summary and Discussion 
 The EpoRepair trial (Erythropoietin for the Repair of 
Cerebral Injury in Very Preterm Infants) is an interna-
tional, multi-center, 1: 1 randomized, double-blind, and 
placebo-controlled clinical trial which aims to evaluate 
the effect of high-dose rEPO on neurocognitive outcomes 
of very preterm infants suffering from established IVH. 
In total, 120 very preterm infants fulfilling the inclusion 
criteria have to be enrolled to achieve a target sample size 
of n = 100 for the secondary end point ‘MRI at TEA’ and 
to achieve a target sample size of n = 80 for the primary 
outcome at 5 years of age (for the sample size calculation, 
see below). The inclusion criteria are as follows: (1) GA at 
birth <32 weeks or birth weight <1,500 g, (2) diagnosis of 
IVH (grade II–IV) assessed by cranial ultrasound accord-
ing to Papile et al.  [4] and (3) chronological age <8 DOL. 
 The study treatment consists of the intravenous 
 administration of rEPO (Epoetin beta ® , Roche, 
 Switzerland) with 2,000 IU/kg BW/dose or of physiolog-
ical saline starting at DOL 5 (±2 days) and repeated 24 h 
and again 48 h later, with all 3 doses being considered 
for loading. A further 2 doses are scheduled for mainte-
nance, at 1 week and 2 weeks after the last loading dose 
(DOL 14 and DOL 21 ±2 days, respectively). The de-
tailed study schedule is given in  figure 1 . Previous stud-
ies in preterm and term infants found 1,000 and 2,500 
IU rEPO/kg BW per dose given intravenously well 
 tolerated and sufficient to produce plasma concentra-
tions that are neuroprotective in animals  [33, 34] . In the 
recently completed first large high-dose rEPO trial in 
very preterm infants, 3,000  IU rEPO/kg BW per dose 
given intravenously were safe  [28] and resulted in prom-
ising brain MRI findings  [29, 30] . In terms of a prag-
matic approach, and also with the aim to add further 
data with regard to the optimal neuroprotective dosing 
in very preterm infants, we opted for an intermediate 
dosage, namely for 2,000 IU/kg BW. 
 The primary end point of our study is the composite 
intelligence quotient (IQ, continuous outcome) at the age 
of 5 years. Normal overall developmental outcome at this 
age will be a secondary end point (binary variable). The 
composite IQ will be measured using the Kaufmann As-
sessment Battery for Children (K-ABC)  [35, 36] . Chil-
dren with hearing or verbal handicaps will be assessed in 
addition by the Snijders-Oomen nonverbal intelligence 
test (SON-R)  [37] . Overall developmental outcome will 
be determined by neurological and formal psychological 
examination and is classified as normal if IQ >84 and 
without one or more of the following: motor impairment, 
cognitive impairment, behavior problems, poor general 
health, severe hearing loss, or bilateral blindness  [38] . 
 Fig. 1. Course of EpoRepair trial. 
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 Other secondary end points are as follows: (1) global 
injury score, WM and gray matter injury scores assessed 
on T1- and T2-weighted images (semiquantitative)  [29] 
and fractional anisotropy using tract-based spatial sta-
tistics (quantitative)  [30] , both in brain MRI at TEA, (2) 
overall severity score of cranial ultrasound findings 
from birth to PMA 36 weeks as published elsewhere  [39] 
(3) Bayley Scales of Infant and Toddler Development 
(BSID-III) at 2 years of corrected age  [40] , including in-
cidence of visual, hearing and motor impairment and 
(4) mortality. 
 The alternative hypothesis for all end points is im-
provement with regard to the end point in the EPO group. 
The null hypothesis for all end points is no improvement 
with regard to the end point in the EPO group compared 
to the control group. Although the study hypotheses are 
one-sided, the tests, however, will be two-sided, yielding 
corresponding confidence intervals and, accordingly, in-
formation about the direction of a potential difference 
between the control and EPO groups. The significance 
level alpha is 0.05.
 The statistical analysis will be done on the following 
levels: (1) confidence intervals will be determined for dif-
ference of IQ and other continuous outcomes between 
the two groups and p values of the corresponding t tests, 
(2) confidence intervals will be determined for risk dif-
ferences and corresponding p values for binary out-
comes, (3) we will adjust for study centers, taking into 
account possible center effects, (4) linear and logistic re-
gression will be used to adjust for additional relevant 
confounding variables with proven impact on outcome 
(e.g. GA and BW) and (5) multiple imputation will be 
used to adjust for missing outcomes due to death or 
dropout  [41] .
 The sample size calculations were based on the follow-
ing considerations and assumptions. Information about 
the effect size and the standard deviation (SD) of the pri-
mary end point (IQ outcome at age of 5 years) can be de-
rived from only one observational study presented by 
Neubauer et al.  [23] , who investigated the effect of rEPO 
treatment in preterm infants on composite IQ at school 
age. The authors included in their study all grades of IVH, 
including the lowest grade, IVH I°. The diagnosis of 
IVH I°, however, may be missed or even overestimated in 
very preterm infants  [42] . Neubauer et al.  [23] reported 
no difference regarding the composite IQ at 10 years be-
tween rEPO-treated and untreated infants without IVH. 
Thus, we decided to exclude infants with the diagnosis of 
IVH I° from our study to avoid bias from misdiagnosis. 
For the relevant group of children who suffered IVH, 
Neubauer et al.  [23] reported an effect size of 23 (SD = 21, 
p < 0.01) between rEPO-treated infants (IQ = 90.3) and 
untreated infants (IQ = 67.0). Given that the vast major-
ity of children remain on their 5-year IQ trajectory, and 
that there is good agreement between classification of 
cognitive abilities at 5 and 11 years of age  [43] , we used 
this continuous outcome parameter (effect size of 23) for 
power analysis based on a X 2 t test assuming a significance 
level of alpha = 5%, SD = 21 of the outcome and a 1: 1 ran-
domization. As a result, we obtained a required total sam-
ple size of n = 28 (for both groups together) and of n = 38 
for a power (1 – beta) of 80 and 90%, respectively. When 
assuming a smaller effect size of 10 (instead of 23 when 
considering the retrospective study design of Neubauer et 
al.  [23] ), an SD of 15 (instead of 21 because IVH °I is ex-
cluded in our study group to avoid misdiagnosis leading 
to a sample which is less heterogeneous with regard to the 
primary outcome) and a power of 80%, the required total 
sample size amounts to n = 72 for the primary end point 
at 5 years of age.
 Based on the only available data of Neubauer et al.  [23] 
and on the above-mentioned reduction of the assumed 
effect size to 10 and of the SD to 15, we set the target sam-
ple size for the secondary end point ‘MRI at TEA’, at n = 
50 for rEPO and n = 50 for placebo. Given an expected 
20% loss to follow-up until 5 years, a sample size of n = 
80 will meet the primary end point. This number is con-
gruent with the result of the power analysis presented 
above. Hence, to achieve the target sample size of n = 100 
for the end point ‘MRI at TEA’ and assuming early loss of 
15% due, for example, to death in this high-risk patient 
population, at least n = 120 preterm infants with IVH II–
IV will have to be enrolled in this trial. Accordingly, if 
early loss exceeds 15%, more infants will need to be en-
rolled to meet the target sample size of n = 100 for the 
secondary end point ‘MRI at TEA’.
 Primarily, it was planned to fill the placebo (physiolog-
ical saline) in the same type of syringes as those manufac-
tured for single-dose usage of rEPO available from vari-
ous pharmaceutical companies. This was considered as 
the most convenient process for blinding, long-term stor-
age and compliance. However, intense negotiations with 
representatives of various pharmaceutical companies, 
different hospital pharmacies and research service pro-
viders revealed insurmountable obstacles averting this 
strategy. After considering alternative strategies, it was 
decided to provide the study medication in new syringes 
for blinding. According to product information for rEPO 
(e.g. from Roche), only plastic materials should be used. 
Since the rEPO stability in vials other than those shipped 
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by the manufacturer has caused some concern  [44–
46] , we performed 6 independent experiments to evaluate 
rEPO stability after storage for variable durations at 4  °  C. 
For each time point the complete content of one 
 Recormon ® PS 3,000 IU/0.3 ml syringe (Roche) was di-
luted in 1.2 ml NaCl 0.9% prefilled syringes (2 ml 
Luer lock;  Codan, Lensahn, Germany) and locked with a 
Combi-Stopper (Arcomed, Regensdorf, Switzerland). 
After storage of 0, 1, 3, or 7 days at 4  °  C, 0.5 ml was eject-
ed in a plastic tube containing 49.5 ml NaCl 0.9% (1: 100 
dilution), of which 10 μl was measured in triplicate with 
a Quantikine IVD Human Epo ELISA (R&D systems) ac-
cording to the manufacturer’s recommendations. As 
shown in  figure 2 , the rEPO stability did not decrease sig-
nificantly when diluted in NaCl 0.9% and stored at 4   °   C 
in plastic syringes for up to 1 week. Statistical significance 
was determined using the matched pairs test. Student’s t 
test was performed for each pair of data separately. p < 
0.05 was considered significant.
 The study has been approved by the leading eth-
ics  committee at the University of Zurich, Switzerland 
(KEK-ZH 2012-0388) and by the Swiss Regulatory Au-
thority, the Swiss Agency for Therapeutic Products 
(Swissmedic 2013DR3204). In Germany the study has 
been approved by the leading ethics committee in Berlin 
and by the Federal Institute for Drugs and Medical De-
vices (EudraCT No. 2014-000612-34). The approval for 
Austria is currently in progress. Written informed con-
sent is required from parents or caretakers. The recruit-
ment for Switzerland began in April 2014 and enrolment 
is calculated to be about 3 years. It is expected that large 
study sites with 120–200 infants <1,500 g BW per year 
(Berlin, Berne, Lausanne, Vienna, Zurich) will each con-
tribute 15–20 study patients and small study sites with 
50–120 infants <1,500 g BW per year (Aarau, Basel, Chur, 
Freiburg, Hannover, Tuebingen, St. Gallen) will each 
contribute 5–10 study patients (ClinicalTrials.gov identi-
fier: NCT02076373.appro).
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 Fig. 2. Stability of rEPO in plastic syringes. Concentrations of 
rEPO (Recormon) are plotted to days of storage and are given rel-
ative to day 0. Data are presented as box (interquartile range) and 
whisker (5–95% range) plots. No significant differences were not-
ed between days of storage. 
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